Attila Marcell Szasz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8492684/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal Analysis of 1α,25-dihidroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer. Cancers, 2022, 14, 658.	1.7	0
2	Deconstructing Immune Cell Infiltration in Human Colorectal Cancer: A Systematic Spatiotemporal Evaluation. Genes, 2022, 13, 589.	1.0	2
3	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942.	1.7	2
4	The human melanoma proteome atlas—Defining the molecular pathology. Clinical and Translational Medicine, 2021, 11, e473.	1.7	14
5	The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome. Clinical and Translational Medicine, 2021, 11, e451.	1.7	20
6	Matrixâ€assisted laser desorption ionization ―mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a nonâ€smallâ€cell lung cancer mouse xenograft model. Clinical and Translational Medicine, 2021, 11, e481.	1.7	1
7	A biobanking turningâ€point in the use of formalinâ€fixed, paraffin tumor blocks to unveil kinase signaling in melanoma. Clinical and Translational Medicine, 2021, 11, e466.	1.7	6
8	Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World Journal of Gastrointestinal Oncology, 2021, 13, 1109-1120.	0.8	4
9	Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study. Diseases (Basel, Switzerland), 2021, 9, 81.	1.0	5
10	Deep Proteomic Analysis on Biobanked Paraffine-Archived Melanoma with Prognostic/Predictive Biomarker Read-Out. Cancers, 2021, 13, 6105.	1.7	3
11	Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database. Cancers, 2021, 13, 6224.	1.7	4
12	Novel functional proteins coded by the human genome discovered in metastases of melanoma patients. Cell Biology and Toxicology, 2020, 36, 261-272.	2.4	9
13	Quo Vadis Oncological Hyperthermia (2020)?. Frontiers in Oncology, 2020, 10, 1690.	1.3	40
14	A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19. Frontiers in Immunology, 2020, 11, 556335.	2.2	1
15	Proteomic analysis enables distinction of early―versus advancedâ€stage lung adenocarcinomas. Clinical and Translational Medicine, 2020, 10, e106.	1.7	7
16	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767.	1.7	2
17	Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice. Cancers, 2020, 12, 3872.	1.7	8
18	Clinical protein science in translational medicine targeting malignant melanoma. Cell Biology and Toxicology, 2019, 35, 293-332.	2.4	33

#	Article	IF	CITATIONS
19	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. Scientific Reports, 2019, 9, 5154.	1.6	12
20	The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. Cancers, 2019, 11, 1981.	1.7	16
21	Challenging the heterogeneity of disease presentation in malignant melanoma—impact on patient treatment. Cell Biology and Toxicology, 2019, 35, 1-14.	2.4	15
22	Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer. Pathology and Oncology Research, 2018, 24, 115-127.	0.9	20
23	Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?. Human Pathology, 2017, 65, 31-40.	1.1	16
24	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nature Communications, 2017, 8, 14944.	5.8	126
25	Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagnostic Pathology, 2017, 12, 20.	0.9	67
26	PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: A comparative study. Breast, 2017, 35, 69-77.	0.9	27
27	Cancer heterogeneity determined by functional proteomics. Seminars in Cell and Developmental Biology, 2017, 64, 132-142.	2.3	17
28	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
29	Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget, 2016, 7, 49322-49333.	0.8	821
30	In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. Diagnostic Pathology, 2016, 11, 61.	0.9	7
31	Reliability of immunocytochemistry and fluorescence in situ hybridization on fineâ€needle aspiration cytology samples of breast cancers: A comparative study. Diagnostic Cytopathology, 2016, 44, 466-471.	0.5	11
32	Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material. Journal of Histochemistry and Cytochemistry, 2016, 64, 256-267.	1.3	16
33	BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters?. Pathobiology, 2016, 83, 1-12.	1.9	9
34	The Petersen prognostic index revisited in Dukes B colon cancer – Inter-institutional differences. Pathology Research and Practice, 2016, 212, 73-76.	1.0	1
35	Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. Journal of Urology, 2016, 195, 1690-1696.	0.2	32
36	Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 551-562.	1.4	6

#	Article	IF	CITATIONS
37	Basaloid carcinoma of the pancreas—clinicopathological presentation and oncogenetic snapshot of a rare entity. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 237-241.	1.4	2
38	Breast- and Salivary Gland-Derived Adenoid Cystic Carcinomas: Potential Post-Transcriptional Divergencies. A Pilot Study Based on miRNA Expression Profiling of Four Cases and Review of the Potential Relevance of the Findings. Pathology and Oncology Research, 2015, 21, 29-44.	0.9	12
39	3-dimensional digital reconstruction of the murine coronary system for the evaluation of chronic allograft vasculopathy. Diagnostic Pathology, 2015, 10, 16.	0.9	17
40	Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. Journal of Clinical Pathology, 2015, 68, 274-282.	1.0	21
41	Current State of ERG as Biomarker in Prostatic Adenocarcinoma. Current Cancer Drug Targets, 2015, 15, 643-651.	0.8	4
42	Intratumor heterogeneity of DNA copy number aberrations in gastric and oesophageal adenocarcinomas Journal of Clinical Oncology, 2015, 33, 78-78.	0.8	0
43	Correlations of Differentially Expressed Gap Junction Connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with Breast Cancer Progression and Prognosis. PLoS ONE, 2014, 9, e112541.	1.1	74
44	Transitional cell and clear cell renal carcinoma: differentiation of distinct histological types with multiphase CT. Acta Radiologica, 2014, 55, 1112-1119.	0.5	17
45	Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology. Journal of Research in Medical Sciences, 2014, 19, 634-8.	0.4	10
46	Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma. International Urology and Nephrology, 2013, 45, 727-733.	0.6	13
47	Expression of HIF1a and HIF2a in bone metastatic clear cell renal cell cancer and use as prognostic markers Journal of Clinical Oncology, 2013, 31, e15523-e15523.	0.8	1
48	The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer. PLoS ONE, 2013, 8, e56707.	1.1	28
49	Genomic alterations in matching primary tumors and metastasis in breast cancer Journal of Clinical Oncology, 2013, 31, 1549-1549.	0.8	0
50	Identifying resistance biomarkers against five clinically approved tyrosine kinase inhibitors in 45 cell lines Journal of Clinical Oncology, 2012, 30, e21005-e21005.	0.8	0
51	Expression of Tight Junction Protein Claudin-4 in Basal-Like Breast Carcinomas. Pathology and Oncology Research, 2009, 15, 59-64.	0.9	55
52	Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer. Oncotarget, 0, 7, 42086-42098.	0.8	19